Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Shares of Voyager Therapeutics (NASDAQ:VYGR) plummeted 20% as the company announced a shift in its gene therapy program for ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

A high-quality genome assembly of Silene latifolia was generated by researchers at CNRS/Université Claude Bernard Lyon 1 and ...

New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

Our gender is identical to our sex, written in our genes, can be clearly assigned and does not change over our lifetime. That's what many people say. The woman on one side, the man on the other ― ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...